Expert Details
Drug Discovery, Neuropharmacology, Serotonin, Dopamine, Antipsychotics, Pharma Project Management
ID: 728553
France
defining target selection and validation criteria, project management, building experimental flow charts, and candidate profiling. He has extensive management experience of multidisciplinary pharmacology research. He has demonstrated proven leadership of project teams including medicinal chemists, early ADMET and preclinical development partners. Collaborations with academic researchers. Participation in Due Diligence and licensing exchanges.
Expert has written numerous publications (>120) in peer-reviewed journals and multiple symposia presentations.
He speaks three languages: English, French, and Italian.
His therapeutic areas of interest include schizophrenia, depression, anxiety / stress, chronic / neuropathic pain and Parkinson’s disease.
Molecular targets characterised: monoamine receptors and transporters, with emphasis on serotonin 5 HT1A and 5-HT2 receptors, dopamine D2, D3 and D4 receptors and alpha2 adrenergic receptors. Additional targets investigated: glutamate NMDA receptors and sodium channels.
Education
| Year | Degree | Subject | Institution |
|---|---|---|---|
| Year: 1992 | Degree: PhD | Subject: Neuropharmacology | Institution: University of Kent at Canterbury |
| Year: 1988 | Degree: BSc | Subject: Biochemistry | Institution: University of Kent at Canterbury |
Work History
| Years | Employer | Title | Department |
|---|---|---|---|
| Years: 2010 to Present | Employer: Undisclosed | Title: Founder | Department: |
Responsibilities:Expert provides strategic consulting in pre-clinical neuropharmacology and drug discovery. Clients are principally biotech and pharmaceutical companies seeking an independent expert opinion on project management, flow-chart and team organisation and drug profiling. Specialty areas: serotonergic mechanisms and antipsychotics. |
|||
| Years | Employer | Title | Department |
| Years: 2002 to 2010 | Employer: Pierre Fabre Laboratories | Title: Director | Department: Neurobiology 2 Division |
Responsibilities:Responsibility for discovery and pharmacological characterisation of novel molecules aimed at treatment of psychiatric disorders (including schizophrenia, depression) and chronic pain. Novel molecules were put into development (F15063: putative antipsychotic; F15599: potential antidepressant / analgesic). Principal therapeutic targets: serotonin 5-HT1A and 5-HT2B, dopamine D2, D3 and D4 receptors.Highly interactive position requiring excellent communication skills, responsibility for staff recruitment and training, progress reports to higher management, participation in drug development teams and preparation of “Due Diligence” dossiers for presentation to potential licensing partners. Direct scientific and administrative management of a multidisciplinary division comprising ~20 FTEs, including 5 Ph.D. scientists. “Dotted-line” management of a further dozen pharmacologists in other departments |
|||
| Years | Employer | Title | Department |
| Years: 1993 to 2002 | Employer: Servier Research Institute | Title: Laboratory Head | Department: Psychopharmacology Division |
Responsibilities:Management of an in vitro pharmacology group consisting of 5 FTEs including a Ph.D. scientist with responsibility for drug screening programme on >20 receptor subtypes and re-uptake sites.Mechanistic investigation of molecular pharmacology of monoamine receptors, including G-protein and MAP kinase activation profiles of dopamine and serotonin receptors. |
|||
Additional Experience
| Marketing Experience |
|---|
| Extensive knowledge of drug discovery process from medicinal chemistry to preclinical development. Expert drug hunter with particular focus on close association of mechanistic innovation ("first in class" drugs) with realistic development criteria. Broad team management and project design experience. |
| Other Relevant Experience |
|---|
| Specialty expertise in serotonin pharmaology and antipsychotics. Widely recognised scientist in pharmaceutical industry (cf. publication record) |
Language Skills
| Language | Proficiency |
|---|---|
| French | Fully fluent |
| Italian | Intermediate level |
Fields of Expertise
brain, catecholamine, central nervous system, drug, drug screening, neurobiology, neuropharmacology, neuropsychopharmacology, neuroscience, pharmaceutical industry, psychopharmacology, serotonin, dopamine, neuropathy, biochemical pharmacology, pharmacodynamics, benzodiazepine, fluoxetine, alpha 2 pharmacology, molecular pharmacology, drug development, nervous system, pharmaceutical drug, neurochemistry, pain management, radiopharmaceutical drug, pharmacology, neuron, nervous system disease, investigational drug